（编辑 楚丽君） 证券日报网讯 11月11日晚间，人民同泰发布公告称，哈药集团人民同泰医药股份有限公司（以下简 称"公司"）股票于2025年11月7日、2025年11月10日、2025年11月11日连续3个交易日内日收盘价格涨幅 偏离值累计超过20%，属于《上海证券交易所交易规则》规定的股票交易异常波动情形。经公司自查， 并向公司控股股东哈药集团股份有限公司、间接控股股东哈药集团有限公司询证，不存在应披露而未披 露的重大事项或重要信息。 ...

Core Viewpoint - The stock of Renmin Tongtai (600829) experienced significant price fluctuations, with a cumulative increase of over 20% in three consecutive trading days, triggering abnormal trading conditions as per Shanghai Stock Exchange regulations [1] Company Summary - Renmin Tongtai announced that it conducted a self-examination and confirmed with its controlling shareholder, Harbin Pharmaceutical Group Co., Ltd., that there are no undisclosed significant matters or important information [1] - The company primarily engages in pharmaceutical wholesale, retail, logistics services, and medical services, with no major changes in its core business operations [1] Market Performance - As of the close on November 11, Renmin Tongtai's stock price was 11.36 yuan per share, reflecting a daily increase of 9.97%, with a total market capitalization of 6.588 billion yuan [1]

证券代码：600829 证券简称：人民同泰 编号：临 2025-030 哈药集团人民同泰医药股份有限公司 股票交易异常波动公告 （一）经公司自查，公司目前经营活动正常，公司不存在其他应披露而未披 露的重大信息。公司所从事的主要业务为医药批发业务、医药零售业务、提供医 药物流服务及医疗服务，主营业务未发生重大变化。 （二）经向公司控股股东哈药集团股份有限公司、间接控股股东哈药集团有 限公司询证确认，本公司控股股东、间接控股股东及间接控股股东的各方股东均 不存在应披露而未披露的影响公司股价异常波动的重大信息，包括但不限于重大 资产重组、股份发行、重大交易类事项、业务重组、股份回购、股权激励、破产 重整、重大业务合作、引进战略投资者等重大事项。 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： ●哈药集团人民同泰医药股份有限公司（以下简称"公司"）股票于 2025 年 11 月 7 日、 2025 年 11 月 10 日、2025 年 11 月 11 日连续 3 个交易日内日收盘价格涨幅偏离值累计超过 20%，属于《上 ...

人民同泰公告，公司股票连续3个交易日内日收盘价格涨幅偏离值累计超过20%，属于股票交易异常波 动情况。经自查，公司目前经营活动正常，不存在其他应披露而未披露的重大信息。公司控股股东及间 接控股股东均不存在应披露而未披露的影响公司股价异常波动的重大信息。公司未发现对公司股票交易 价格产生重大影响的重大事件，未发现需要澄清或回应的媒体报道或市场传闻。 ...

Core Insights - The flu season in China is expected to start earlier than usual, with respiratory diseases entering a high incidence period [1][4] - A surge in flu-related stocks has been observed in the A-share market, with significant gains for companies like Weikang Pharmaceutical and Te Yi Pharmaceutical [2][3] Industry Overview - The China CDC has reported an increase in flu activity in southern provinces, indicating a potential early onset of the flu season [4] - Experts predict that the peak of the flu epidemic may occur in late December to early January, with a notable shift in circulating strains from H1N1 to H3N2, leading to lower immunity in the population [5][6] Market Response - Flu concept stocks have shown strong performance, with Weikang Pharmaceutical rising over 12% and several other companies reaching their daily limit [2][3] - The demand for antiviral medications is expected to surge as the flu season approaches, prompting pharmaceutical companies to ramp up production [8] Investment Opportunities - The year 2025 is anticipated to be a pivotal year for domestic flu medications, with several innovative drugs expected to receive approval, presenting both short-term and long-term investment opportunities [8] - The low vaccination rates in China highlight the urgent need for a comprehensive flu management system, which could benefit key sectors such as vaccine development, infection control, and antiviral drug production [8]

Group 1 - The flu season in China is expected to peak earlier this year, potentially in late December to early January, due to rising flu activity in southern provinces and different circulating strains compared to last year [4][5]. - The dominant strain this year is expected to be H3N2, which may lead to lower immunity in the population compared to last year's H1N1 strain [5]. - The demand for antiviral medications is anticipated to surge as the flu peak approaches, with several pharmaceutical companies ramping up production [8]. Group 2 - A-share flu-related stocks have shown strong performance, with notable increases in companies such as Weikang Pharmaceutical (+12.08%), Te Yi Pharmaceutical (+10.00%), and Renmin Tongtai (+9.97%) [2][3]. - The flu vaccine and antiviral drug sectors are expected to benefit from the anticipated increase in flu cases, highlighting a dual opportunity for investors in both short-term pandemic catalysts and long-term innovation [8]. - The overall flu-related industry, including vaccine development, infection control, and antiviral drugs, is likely to see a demand surge and value reassessment during the flu season [8].

Core Viewpoint - The SPD index experienced a 2% increase, with notable performances from several constituent stocks, indicating positive market sentiment and potential investment opportunities in the sector [1] Group 1: Stock Performances - The stock of Cheung Fat China reached its daily limit up, reflecting strong investor interest and confidence [1] - Renmin Tongtai also hit its daily limit up, suggesting robust trading activity and positive market dynamics [1] - Huaren Health saw a rise of 7.47%, indicating strong performance and potential growth prospects [1] - Shuyupingmin increased by 6.30%, showcasing positive investor sentiment [1] - Yaoyigou experienced a 5.78% increase, further highlighting the upward trend in the market [1]

Market Overview - The A-share market is expected to experience a balanced market style, with the Shanghai Composite Index likely consolidating around the 4000-point level [1][9]. - The long-term positive trend of the A-share market remains unchanged, with attention on themes such as anti-involution and dividends during sector rotations [9]. Economic Policies - The State Council has issued measures to promote private investment, including 13 targeted policy initiatives aimed at encouraging private capital participation in key sectors like railways and nuclear power [5]. - The National Development and Reform Commission and the National Energy Administration have released guidelines to enhance the consumption and regulation of renewable energy, aiming for a multi-layered system by 2030 [6]. Corporate Developments - Ganfeng Lithium has made significant progress in developing the PPGS lithium salt lake project in collaboration with LAR [9]. - A major asset sale by Wingtech Technology has been completed, although some payments remain outstanding [9]. - Shandong Gold's subsidiary is required to pay back taxes amounting to 738 million yuan, which is expected to impact the company's net profit for 2025 by 230 million yuan [8]. Stock Market Movements - The U.S. stock market saw significant gains, with the Dow Jones Industrial Average rising by 0.81%, the Nasdaq by 2.27%, and the S&P 500 by 1.54% [4]. - Notable technology stocks performed well, with Nvidia increasing by 5.8% and Google by 3.9% [4]. Commodity Prices - International oil prices have risen, with WTI crude oil increasing by 0.64% to $60.13 per barrel and Brent crude by 0.68% to $64.06 per barrel [4]. - Gold prices surged, with COMEX gold futures for November delivery rising by 2.81% to $4111.80 per ounce [4].

Core Insights - The pharmaceutical commercial sector experienced a rise of 1.82% on November 10, with Renmin Tongtai leading the gains [1] - The Shanghai Composite Index closed at 4018.6, up 0.53%, while the Shenzhen Component Index closed at 13427.61, up 0.18% [1] Pharmaceutical Sector Performance - Renmin Tongtai (600829) closed at 10.33, with a significant increase of 10.01% and a trading volume of 308,800 shares, amounting to a transaction value of 313 million yuan [1] - Other notable performers included: - Mizheng Pharmaceutical (002788) at 10.25, up 6.66% with a volume of 545,100 shares [1] - Huaren Health (301408) at 15.00, up 5.41% with a volume of 343,000 shares [1] - HeFu China (603122) at 16.60, up 5.26% with a volume of 1,151,100 shares [1] Capital Flow Analysis - The pharmaceutical commercial sector saw a net inflow of 322 million yuan from institutional investors, while retail investors experienced a net outflow of 120 million yuan [2] - The main capital flow for Renmin Tongtai showed a net inflow of 139 million yuan, accounting for 44.32% of its trading volume [3] - Other companies with significant net inflows included: - HeFu China with a net inflow of 99.5 million yuan [3] - Laobaixing with a net inflow of 36.1 million yuan [3]

Group 1 - The pharmaceutical commercial sector experienced an initial rise on November 10, with notable stocks such as Renmin Tongtai hitting the daily limit increase [1] - Other companies that followed the upward trend include Hefei China, Huaren Health, Rundat Medical, Saili Medical, and Shuyupingmin [1]